Candiflu 50 mg/5 ml (Powder for Suspension)
Medicine Details
| Category | Details |
|---|---|
| Generic | Fluconazole |
| Company | Globex pharmaceuticals ltd |
| Also available as |
Indications
- Vaginal Candidiasis
- Oropharyngeal Candidiasis
- Oesophageal Candidiasis
- Tinea corporis/Tinea cruris/Tinea pedis/Other Tinea
- Kerion
- Pityriasis versicolor
- Onychomycosis
- Invasive candidal infections and cryptococcal infections (including meningitis)
- Prevention of cryptococcal meningitis
- Prevention of fungal infections in immunocompromised patients
- Systemic Candidiasis and Cryptococcal infection
- Fungal urinary tract infections
- Disseminated candidiasis
- Prophylaxis for fungal infection in neutropenic cancer patients
- Acute treatment of other systemic fungal infections such as coccidioidomycosis and histoplasmosis
Pharmacology
Triazole antifungal agent, potent inhibitor of fungal cytochrome P-450 dependent enzymes, responsible for the synthesis of ergosterol
Dosage & Administration
- 150 mg as a single dose for Vaginal Candidiasis
- 200 mg in 1st day followed by 100 mg daily for 14 days for Oropharyngeal Candidiasis
- 200 mg in 1st day followed by 100 mg daily for 14-30 days for Oesophageal Candidiasis
- 150 mg weekly for 4-6 weeks for Tinea corporis/Tinea cruris/Tinea pedis/Other Tinea
- 50 mg daily for 20 days for Kerion
- 400 mg as a single dose for Pityriasis versicolor
- 150 mg weekly for 12 months for Onychomycosis
- 400 mg on first day then 200-400 mg daily for Invasive candidal infections and cryptococcal infections (including meningitis)
- 200 mg daily for Prevention of cryptococcal meningitis
- 50-400 mg daily for Prevention of fungal infections in immunocompromised patients
- 1-2 mg/kg daily for Superficial Candidiasis
- 3-6 mg/kg daily for Systemic Candidiasis & Cryptococcal infection
- Dosage interval modified based on renal clearance for Renal Impairment
- Doses up to 12 mg/kg recommended for children aged 5-13 years
Interaction
- Increased prothombin time after warfarin administration
- Prolonged serum half-life of concomitantly administed oral sulphonyl ureas
- Increased plasma concentrations of fuconazole with co-administration of multiple-dose hydrochlorothiazide
- Increase in the level of phenytoin with co-administration of fuconazole
- 25% decrease in the AUC and 20% shorter half-life of fuconazole with administration of fuconazole and rifampicin
- No relevant effects on hormone levels in the 50 mg fuconazole study
- Slow increase in cyclosporin concentrations with fuconazole 200 mg daily
- No clinically significant impairment of fuconazole absorption when co-administered with food, cemetidine, antacids, or following total body irradiation for bone marrow transplantation
- 18% decrease in the mean plasma clearance of theophyline after administration of fuconazole 200mg for 14 days
Contraindications
Not to be used in patients with known hypersensitivity to Fluconazole or to related triazole compounds
Side Effects
Common side effects include symptoms associated with the gastrointestinal tract, such as nausea, abdominal discomfort, diarrhea, and flatulence. Rare adverse events such as rash and anaphylaxis reported
Pregnancy & Lactation
Adverse fetal effects seen in animals only at dose levels associated with maternal toxicity, hence not recommended in pregnancy or in women of child bearing potential unless adequate contraception is employed
Precautions & Warnings
- Abnormalities of hepatic, renal, haematological and other biochemical function tests observed in some patients, particularly those with serious underlying diseases such as AIDS and cancer
- Rare instances of hepatic necrosis reported in patients receiving multiple dose fuconazole
- Rare cases of exfoliative cutaneous reactions observed, particularly in AIDS patients
Use in Special Populations
- Normal dose recommended for the elderly if no evidence of renal impairment
- No adjustments in single dose therapy required for renal impairment
- Dosage intervals or daily dosage should be adjusted based on creatinine clearance for patients with renal impairment
Overdose Effects
Supportive measures and symptomatic treatment with gastric lavage if necessary may be adequate, forced volume diuresis might increase the elimination rate, haemodialysis decreases plasma levels by approximately 50%
Therapeutic Class
Drugs for subcutaneous and mycoses
Storage Conditions
Keep in a dry place away from light and heat, keep out of the reach of children